EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, DMK Pharmaceuticals's enterprise value is $0.02 Mil.
DMK Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $3.62 Mil. Therefore, DMK Pharmaceuticals's EV-to-Revenue for today is 0.01.
The historical rank and industry rank for DMK Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
DMKPQ'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1.76 Med: 8.2 Max: 91.11
Current: 0.01
During the past 13 years, the highest EV-to-Revenue of DMK Pharmaceuticals was 91.11. The lowest was -1.76. And the median was 8.20.
DMKPQ's EV-to-Revenue is ranked better than 98.54% of 1024
companies
in the Drug Manufacturers industry
Industry Median: 2.37
vs DMKPQ: 0.01
The historical data trend for DMK Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DMK Pharmaceuticals's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DMK Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where DMK Pharmaceuticals's EV-to-Revenue falls into.
DMK Pharmaceuticals's current Enterprise Value is $0.02 Mil.
DMK Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals's share price for today is $0.0333.
DMK Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.67.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMK Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of DMK Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMKPQ has been successfully added to your 